Agents such as gonadotropin-releasing hormone agonists (GnRHa), tamoxifen, medroxyprogesterone, or letrozole (an aromatase inhibitor) are used to diminish the growth of the residual tumor or disease recurrence, particularly in cases with margin-positive resection or inoperable disease [2,7,8]. The gene discussed is CYP19A1; the disease is neoplasm.